Document is current
Any future updates will be listed below
-
Authors
Fredericksen, R.J.
Nance, R.M.
Drumright, L.N.
Mixson, L.S.
Ruderman, S.A.
Whitney, B.M.
Fahey, C.
Mayer, K.H.
Jain, J.P.
Saag, M.
Eron, J.
Napravnik, S.
Bamford, L.
Cachay, E.
Yendewa, G.A.
Keruly, J.
Moore, R.D.
Rodriguez, A.
Safren, S.
Delaney, J.A.C.
Crane, H.M.
Hahn, A.W.
-
Funding
Funding for this research was provided by:
National Institute of Allergy and Infectious Diseases (R24 AI067039, P30 AI027757, P30 AI027767)
National Institute on Drug Abuse (R01DA047045, R01DA058938, U24DA058307)
- License Information
-
More Information
Article History
Accepted: 31 August 2025
First Online: 29 September 2025
Declarations
:
: E. Cachay has received unrestricted research grants paid to the University of California Reagents from Gilead Sciences for unrelated hepatitis C virus research projects and has received payment honoraria from Gilead Science (symposium, educational event November 2021) and THERATechnologies (advisory board consulting fees for an unrelated topic in 2022). K. Christopoulos has been a medical advisory board member for Gilead and a workshop participant for Janssen. J. Eron declares research funding from Gilead Sciences and ViiV Healthcare University of North Carolina-Chapel Hill as an investigator, and consulting fees paid to him from Merck & Co, ViiV Healthcare and Gilead Sciences. All other authors declare no conflicts of interest.
